Exhibitor Registration Soars as COMPUTEX Debuts New Exhibits
Since its establishment in 1981, COMPUTEX TAIPEI has witnessed the evolution of Taiwan’s and the world’s ICT industry. The show’s position in Taiwan makes it a vital link in the island’s complete supply chain, as well as a professional platform for companies from all over the world to release new products and technologies.
Domestic exhibitor registration for the 2016 COMPUTEX show was completed in December of 2015. Confirmed exhibitors include Acer, Asus, MediaTEK, and Advantech, as well as early overseas registrations like Intel, Microsoft, Haier, Siemens, Hisense, and Supermicro. Registration for overseas exhibitors is still open, and COMPUTEX continues to receive applications. The combined scale of the show is expected to exceed 5000 booths, a clear sign of the exhibitors’ faith in this professional show.
COMPUTEX has a new positioning in 2016, which is to become the ideal platform for Building Partnerships in Internet Computing Ecosystems. The Internet of Things, innovation and startups, and business solutions make up the show’s major themes as part of its mission to read the pulse of the newest waves in smart technology.
In conjunction with the show’s themes, the show organizers—the Taiwan External Trade Development Council (TAITRA) and the Taipei Computer Association (TCA)—have specially organized three new exhibits to debut in the 2016 show: SmarTEX, InnoVEX, and iStyle.
SmarTEX will be unveiled in TWTC Exhibition Hall 1 and focuses on the major applications of the Internet of Things in security and safety, home and entertainment, wearables, automotives, 3D printing, and smart technologies.
InnoVEX is a startup village that will operate out of TWTC Exhibition Hall 3, featuring out-of-the-box, open booths and networking spaces to create a matchmaking platform between investors and startups, as well as a series of forums, demos, and networking sessions to maximize innovative, technological, and investment exchanges.
The new iStyle exhibit will be held in Taipei Nangang Exhibition Center Hall 1, featuring Apple-certified peripherals and apps.
The 2016 COMPUTEX d&i awards have also added two new categories, Wearable Technology + Smart Applications/Products and Smart Home + Security, in response to the shifting industry and rise of startups, as well as a new award, the COMPUTEX d&i Rising Star award, to encourage participation from startups.
COMPUTEX continues its efforts to enhance its services for exhibitors and buyers. The show won the UFI Marketing Award in 2014 and the AFECA Award for Outstanding Trade Exhibition in 2015. Winning international awards for outstanding trade shows 2 years in a row is an unprecedented honor in Taiwan’s MICE history.
COMPUTEX stands at the forefront of the world’s technological applications. The official website and smartphone app will release all-new versions in 2016, featuring new visuals and optimized user interfaces that are both user-friendly and mobile-friendly for a comprehensively improved user experience. The buyers’ badges will continue to incorporate metro pass functions with RFID technology, and visitors can take advantage of the Wi-Fi in all the venues to enjoy the greatest convenience COMPUTEX can offer.
Note to Editors: The official name of our event is “COMPUTEX TAIPEI.” We also accept “COMPUTEX”.
TAITRA, Taiwan External Trade and Development Council, organized 36 exhibitions in 2015. A total of 11,475 international and local exhibitors participated, occupying 32,982 booth spaces and visited by 82,939 international visitors.
About COMPUTEX TAIPEI:
Established in 1981, COMPUTEX TAIPEI is the leading global ICT show with a complete supply chain. Co-organized by the Taiwan External Trade Development Council (TAITRA) and the Taipei Computer Association (TCA), COMPUTEX TAIPEI plays off its proximity to Taiwan’s ICT cluster to cover the whole spectrum of ICT from upstream components-manufacturing all the way to system assembly and IoT applications. With over a third of the world’s computing devices made by Taiwanese companies, Taipei is a logical destination for buyers looking for partners in Internet computing ecosystems. Follow COMPUTEX TAIPEI online at www.computextaipei.com.tw.
Exhibition Dept., TAITRA
Stacy Feng, +886-2-2725-5200 Ext. 2639
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom